
A


Percent Seizure
120
100
80
60
40
20
0
89 ng/mL
(283 nM)
344 ng/mL
(1.09 uM)
878 ng/mL
(2.79 uM)
*
Saline
MPEP 30mg/kg
30% Captisol
3
10
30
Allopregnanolone

B




Percent Survival
120
100
80
60
40
20
0
*
Saline
MPEP 30mg/kg
30% Captisol
3
10
30
Allopregnanolone

FIG. 1

A


15% HPβCD (i.p.) - PTZ (85 mg/kg, i.p.)
Valproate (400 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.)
SGE-102 (3 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.) - 88.2 ng/mL
SGE-102 (10 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.) - 321 ng/mL
SGE-102 (30 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.) - 673 ng/mL
Seizure Rank (0-6)
0
2
4
6
8
10
10
20
30
Time (min)

B



15% HPβCD (i.p.) - PTZ (85 mg/kg, i.p.)
Valporate (400 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.)
SGE-102 (3 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.)
SGE-102 (10 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.)
SGE-102 (30 mg/kg, i.p.) - PTZ (85 mg/kg, i.p.)
Latency to death (sec)
0
500
1000
1500
2000
2500
3000

FIG. 2



Plasma Exposure of ALLO from Human SE Study (LLOQ 16nM)
PLASMA (nM)
160
140
120
100
80
60
40
20
0
-2
9
19
29
39
49
59
69
79
89
99
109
119
129
139
HOURS
Dosing Schedule
ALLO 1.5 mg/mL(1-120 hrs)

FIG. 3




Table 1.

Time point (hr)	% Difference Plasma IM relative to IV
0.5	838.26%
1	916.52%
2	671.92%

FIG. 4A




Table 2.

Time point (hr)	% Difference Brain IM relative to IV
1	506.17%

FIG. 4B



SAGE (Captisol) Formulation; IV Chronic x 5d
LATENCY TO FALL (sec)
0
10
20
30
40
50
60
70
SHAM (10)
PBBI_VEH (10)
LOW PROG (8)
HIGH PROG (12)
10 rpm
15 rpm
20 rpm
PRE-PBBI
DAY 6
DAY 9

FIG. 5A



MEAN MOTOR SCORE
p = .06 vs. PBBI
MEAN MOTOR/BALANCE SCORE
45
40
35
30
25
20
15
10
5
0
PBBI
2.5/1.25
5.0/2.50
SAGE (mg/kg/hx5d)

FIG. 5B